Cognition Therapeutics
CGTX
45 hedge funds and large institutions have $7.78M invested in Cognition Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
291% more capital invested
Capital invested by funds: $1.99M → $7.78M (+$5.78M)
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
16.09% more ownership
Funds ownership: 10.6% → 26.69% (+16%)
13% more funds holding
Funds holding: 40 → 45 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$247K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$206K |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.2K |
| 4 |
Two Sigma Investments
New York
|
+$20.9K |
| 5 |
SG Americas Securities
New York
|
+$18.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$77.5K |
| 2 |
TCBWMS
Texas Capital Bank Wealth Management Services
Dallas,
Texas
|
-$26K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$24.7K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$22.2K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$15.2K |
CGTX Hedge Fund Activity: Q4 2024 in Review
45 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q4 2024, worth a combined $7.78M — up 291% from $1.99M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CGTX positions and 2 closed out — a net gain of 6 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was Voss Capital, opening a new position worth an estimated $247K. The largest seller was UBS Group, cutting an estimated $77.5K.
- 45 institutional investors held Cognition Therapeutics (CGTX) as of Q4 2024, up from 40 in Q3 2024.
- Funds reported $7.78M of Cognition Therapeutics stock for Q4 2024, up 291% quarter-over-quarter.
- 8 funds opened new Cognition Therapeutics positions in Q4 2024 and 2 closed out, a net change of +6 holders.
- The largest Cognition Therapeutics buyer in Q4 2024 was Voss Capital, an estimated $247K added.
- The largest Cognition Therapeutics seller in Q4 2024 was UBS Group, an estimated $77.5K sold.
Based on aggregated 13F filings for Q4 2024.